RESUMO
The diagnostic reference level (DRL) is a patient-exposure optimization tool used to evaluate and provide guidance for radiation doses in medical imaging. In the past few decades, there has been a global increase in the number of diagnostic imaging procedures, including nuclear medicine procedures, and consequently in patient radiation exposure. This increase has encouraged international and national health-care organizations to take action and keep up with such changes to meet the expectation of increasing use of ionizing radiation in medicine. Methods: DRLs in Kuwait were established by investigating the administered activity of radiopharmaceuticals and CT radiation doses in hybrid imaging systems. The DRLs were determined on the basis of the 75th percentile of radiopharmaceutical administered activity distribution as recommended by the International Commission on Radiological Protection. Results: The DRLs determined in Kuwait agree well with other published DRLs in Europe, Japan, Korea, Australia, and the United States. Conclusion: This study presents the establishment process and the results of the first national DRLs for nuclear medicine procedures in Kuwait as a way to optimize radiation exposure.
Assuntos
Medicina Nuclear , Níveis de Referência de Diagnóstico , Humanos , Kuweit , Imagem Multimodal , Doses de Radiação , Valores de ReferênciaRESUMO
The aim of this study is to investigate the relationship between brown adipose tissue (BAT) activation and myocardial fluorine-18-fluorodeoxyglucose ([18F] FDG) uptake in terms of intensity and patterns. The patients were divided into two groups as follows: BAT and control groups. The BAT group consists of 34 cases that showed BAT uptake. The control group, with no BAT uptake, included 68 patients who were matched for body mass index, gender, and season. The scans were retrospectively reviewed by two nuclear medicine physicians who visually evaluated the intensity of myocardial [18F] FDG uptake. The myocardial [18F] FDG uptake was visually classified into the following three patterns: diffuse, heterogeneous, and focal. The regions of activated BAT distribution were noted. The mean myocardial [18F] FDG uptake was 2.50 ± 0.75 for the BAT group and 2.13 ± 0.88 for the control group with a statistically significant difference (P = 0.031). The myocardial [18F] FDG uptake pattern was similar in the BAT and control groups with the diffuse pattern being the most common, followed by the heterogeneous and less commonly focal. In the BAT group, the anatomical distribution of BAT was mainly in supraclavicular, paravertebral, and axillary and to a lesser extent in cervical regions. BAT group had a significantly higher intensity of [18F] FDG myocardial uptake compared to that of the control group. The presence of activated BAT did not affect the pattern of myocardial uptake. Knowledge of these findings may help in understanding the variability of myocardial [18F] FDG uptake and consequently in avoiding misinterpretation of cardiac findings in positron-emission tomography/computed tomography studies.
RESUMO
AIM: This study was carried out to compare the efficacy of Y, Lu, and combination of both radiotracers (tandem) peptide receptor radionuclide therapy (PRRT) in patients with inoperable and metastatic neuroendocrine tumors. MATERIALS AND METHODS: Systematic searches of PubMed and SciVerse Scopus databases were performed till December of 2016. The data were categorized into three groups: Y-PRRT, Lu-PRRT, and tandem-PRRT. Each group was subdivided on the basis of the response criteria used: Response Evaluation Criteria in Solid Tumors (RECIST) or Southwest Oncology Group (SWOG) criteria. Disease response and disease control rates of each group were analyzed. RESULTS: For the RECIST group, Y-PRRT disease response rates ranged from 22.81 to 56.1%, with a pooled random effect of 42.92%, and the disease control rate was 100%. Lu-PRRT disease response rates ranged from 27.63 to 57.35%, with a pooled random effect of 33.41%, and disease control rates ranged between 71.88 and 100%, with a pooled fixed effect of 79.32%. As for tandem-PRRT, disease response rates ranged between 42.11 and 66.67%, with a pooled fixed effect of 50.52%, and the disease control rate ranged between 93.33 and 100%, with a pooled fixed effect of 98.97%.For the SWOG group, Y-PRRT disease response rates ranged from 5.13 to 26.56%, with a pooled random effect of 13.4%, and disease control rates ranged between 76.56 and 85.9%, with a pooled fixed effect of 80.93%. Lu-PRRT disease response rates ranged from 6.06 to 60.29%, with a pooled random effect of 26.4%, and the disease control rates between 48.48 and 85.29%, with a pooled random effect of 74.53%. CONCLUSION: Y-PRRT had the highest disease control rates under both RECIST and SWOG criteria. Tandem-PRRT had the highest disease response rate in the RECIST criteria, indicating that PRRT should be customized to each patient individually for maximum benefit.